Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Data to Be Presented at CRI Immunotherapy Conference Show PS-Targeting Antibodies Enhance the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Decreasing Levels of Myeloid Derived Suppressor Cells (MDSC) in the Tumor M PPHM.O - MKW
06-Oct-2014 14:00
For best results when printing this announcement, please click on the link below:
http://pdf.reuters.com/pdfnews/pdfnews.asp...
Data to Be Presented at CRI Immunotherapy Conference Show PS-Targeting Antibodies Enhance the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Decreasing Levels of Myeloid Derived Suppressor Cells (MDSC) in the Tumor Microenvironment
UTSW Collaborators Found Phosphatidylserine (PS)-Targeting Antibody in Combination With an Anti-PD-1 or an Anti-CTLA-4 Immune Checkpoint Inhibitor Promotes a Robust, and Localized Anti-Tumor Response in Models of Melanoma and Breast Cancer; Statistically Significant Tumor Growth Suppression With Combination of PS-Targeting Antibody and Anti-PD-1 Versus Antibody Alone in Breast and Melanoma Models; Lead PS-Targeting Antibody Bavituximab in a Phase III Trial in Second-Line Non-Small Cell Lung Cancer and a First Immunotherapy Combination Trial With Ipilimumab (Yervoy(R)) in Advanced Melanoma
TUSTIN, CA--(Marketwired - Oct 6, 2014) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced the presentation of preclinical data related to the company's immuno-oncology development program and its lead drug candidate bavituximab, a phosphatidylserine (PS)-targeting antibody. Data show that PS-targeting agents in combination with immune checkpoint inhibitors, such as anti-PD-1 or anti-CTLA-4, promote a robust and localized anti-tumor response in models of melanoma and breast cancer and decrease levels of myeloid derived suppressor cells (MDSC) in the tumor microenvironment. Newly generated data show that the combination of a PS-targeting antibody equivalent to bavituximab administered with an anti-PD-1 antibody displayed statistically significant tumor growth suppression compared to anti-PD-1 antibody treatment alone in an animal model of melanoma. These data will be presented this morning at the Cancer Research Institutes' "Cancer Immunotherapy: Out of the Gate" conference being held at the Grand Hyatt Hotel in New York, New York.
"We are pleased to be presenting this exciting data to this immuno-oncology focused audience," said Jeff T. Hutchins, Ph.D. vice president, preclinical research at Peregrine Pharmaceuticals "These data are impressive and consistent in their findings across several tumor types and further build on the rationale for additional collaborative studies such as the ongoing investigator-sponsored Phase Ib trial of bavituximab in combination with ipilimumab (Yervoy®) in advanced melanoma."
The poster titled: "Antibody-mediated blockade of phosphatidylserine enhances the anti-tumor activity of immune checkpoint inhibitors by affecting myeloid-derived suppressor cell (MDSC) and lymphocyte populations in the tumor microenvironment" will be presented by Rolf Brekken, Ph.D., Effie Marie Cain Research Scholar in Angiogenesis Research and an Associate Professor, in the Departments of Surgery and Pharmacology at the Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center in Dallas, Texas. Data from these studies show that the PS-targeting antibody ch1N11, the preclinical equivalent to bavituximab, significantly enhances tumor growth inhibition of anti-CTLA-4 or anti-PD-1 in the B16 and K1735 melanoma models and the efficacy of anti-PD-1 in the EMT-6 breast tumor model. New data show that the combination of ch1N11 and an anti-PD-1 antibody produce a statistically significant difference (p=0.018) in tumor growth suppression over anti-PD-1 alone in the B16 melanoma model. In addition, PS blockade with ch1N11 combined with either anti-CTLA-4 or anti-PD-1 resulted in greater T cell infiltration into B16 and K1735 tumors than tumors treated with either antibody alone. Consistent with these results, ch1N11 combined with anti-PD-1 showed an enhanced percentage of T cells producing the cytokines IL-2 and IFNg, factors associated with immune activation, when compared with T cells from tumors being treated with anti-PD-1 alone. In summary, the targeting and blocking of PS with ch1N11 significantly improved the anti-tumor efficacy of immune checkpoint blockade in robust models of melanoma and breast cancer in immunocompetent animals.
The link to the poster can be found from the front page of the company's website at: www.peregrineinc.com.
About Peregrine Pharmaceuticals, Inc.
At the ende you find PPHM 1202 SUNRISE
http://www.doctaforum.net/congresos/gestor/ckfinder/userfiles/files/caom/presentaciones/S6.1_Cortes-Funes.pdf
Haven´t seen it before:
http://www.partnering360.com/dynfiles/feature/upload/comp_23381/Cancer_Immunotherapies_Report.pdf
Search for Bavituximab or Peeregrine in the text
Lot of Info - i found different News under: Google.AT or .de or .IT
Try my luck again tomorow
CP, thx for your "translation"
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=106891625
When i found it today, i thought this document is not for our eys!
i like that Italian-English!!!
http://www.dovepress.com/profile-of-bavituximab-and-its-potential-in-the-treatment-of-non-small-peer-reviewed-article-LCTT
watch the Video!!!
you can find that protocol also over their homepage:
http://www.hsgerardo.org/web/guest/ricercaportale?p_p_auth=aEKI3tit&p_p_id=15&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&p_p_col_id=column-3&p_p_col_count=1&_15_struts_action=%2Fjournal%2Fview_article&_15_groupId=10179&_15_articleId=18585&_15_version=7
http://www.hsgerardo.org/8.6
such for: pphm 1202 or SUNRISE
Italy again - but what is that?
http://www.hsgerardo.org/documents/10179/6595611/240.pdf/74a30259-173e-4e3a-a9a2-0ba413672a43
is this something old?
http://www.science.gov/scigov/result-list/fullRecord:Bavituximab/
another "italian-seach": and found that...
http://www.centerwatch.com/clinical-trials/listings/ctrc/condition/683/non-small-cell-lung-cancer/?mp=pcf#Italy
most of them are really beautiful italian cities
from an italian Google-page:
Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
28. August 2014
insert-text-here
http://www.dovepress.com/profile-of-bavituximab-and-its-potential-in-the-treatment-of-non-small-peer-reviewed-article-LCTT
www.dovepress.com/getfile.php?fileID=21396
$ 1,40 PM
Phosphatidylinositol
http://en.wikipedia.org/wiki/Phosphatidylinositol
German Wiki:
http://de.wikipedia.org/wiki/Phosphatidylinositol-4,5-bisphosphat
Ther you find: Phospholipiden (Link in the first line)
http://de.wikipedia.org/wiki/Phospholipide
and there you find OUR PS!!!
ESMO news
Has something to do with our PS
http://www.esmo.org/Conferences/ESMO-2014-Congress/News-Articles/Pathway-of-the-Day-PI3K-AKT-mTOR
You are right - i´m just scanning Bayer Healthcare nearly every day to find "something"!.
ESMO 2014 - Brest Cancer - but nothing found from Bavi or PPHM
http://www.esmo.org/Oncology-News?&filter[]=extra_ezobjectrelationlist_topics_names____ms:"Breast%20cancer"&activeFacets[extra_ezobjectrelationlist_topics_names____ms:Topics]=Breast%20cancer
ESMO Immuno:oncology Geneva 21-22 Nov. with David Carbone
Saturday, 22 November 2014
http://www.esmo.org/content/download/41727/790129/file/ESMO-Symposium-on-Immuno-Oncology-2014-Programme.pdf
From Bayer HealthCare Homepage: NEXAVAR
We are jointly developing and commercializing our cancer drug Nexavar[color=red][/color]™ (active ingredient: sorafenib) with Onyx Pharmaceuticals, Inc., United States. The successful active ingredient sorafenib, which targets both cancer cells and the vascular system of the tumor, has been registered for the treatment of advanced renal cell carcinoma since 2005 and hepatocellular carcinoma since 2007. We plan to develop the product beyond these two therapeutic areas with a broadly based life-cycle management program. Based on the clinical Phase III DECISION study, we submitted sorafenib to the European Medicines Agency (EMA) and the FDA in June 2013 for regulatory approval in the treatment of locally advanced or metastatic differentiated thyroid cancer refractory to radioactive iodine. The FDA granted this approval in November 2013 following a priority review. In September 2013, sorafenib was submitted to the Japanese MHLW for marketing authorization for the treatment of thyroid cancer. Sorafenib is also being investigated in Phase III registration studies as an adjuvant therapy following curative tumor resection in patients with renal cell carcinoma or hepatocellular carcinoma. We are also conducting Phase III registration studies in breast cancer.
[color=red][/color]
Nothing to read from BAVI - i just found SORAFENIB
News from BAYER coming!
http://press.healthcare.bayer.com/en/press/news-details-page.php/15640/2014-0326
ESMO 2014 to Feature New Oncology Data from Across Bayer Franchise
Positive Results of the Phase III CONCUR trial of regorafenib in Asian patients with metastatic colorectal cancer to be presented in Proffered Paper Session / Includes data from studies evaluating regorafenib, sorafenib and radium Ra 223 dichloride across six tumor types
Berlin, September 24, 2014 – Bayer HealthCare announced today that data from its oncology portfolio, including Stivarga® (regorafenib) tablets, Nexavar® (sorafenib) tablets and Xofigo® (radium Ra 223 dichloride) injection, will be presented at the European Society for Medical Oncology (ESMO) 2014 Congress taking place September 26 – 30 in Madrid, Spain. These data include an oral presentation on the Phase III CONCUR trial evaluating the efficacy and safety of regorafenib in Asian patients with previously treated metastatic colorectal cancer (mCRC).
“Bayer’s presence at this global conference demonstrates our commitment and progress in exploring new treatment options for cancer patients around the world across various tumor types through both our robust portfolio and pipeline,” said Dr. Joerg Moeller, Member of the Bayer HealthCare Executive Committee and Head of Global Development.
Notable studies evaluating Bayer's oncology products at ESMO 2014 are listed below.
Regorafenib
- CONCUR: A randomized, placebo-controlled phase 3 study of regorafenib (REG) monotherapy in Asian patients with previously treated metastatic colorectal cancer (mCRC)
- Oral Presentation 500O, Proffered Paper Session: Gastrointestinal tumors, colorectal
- Saturday, September 27, 10:20 – 10:35 AM (CET), Madrid Room
- REBECCA: A large cohort study of Regorafenib (REG) in the real-life setting in patients (pts) previously treated for metastatic colorectal cancer (mCRC)
- Abstract 602P, Poster Display Session: Gastrointestinal tumors, colorectal
- Monday, September 29, 12:45 – 1:45 PM (CET), Poster Area
- The Cost of Survival Gains in Metastatic Colorectal Cancer (mCRC) in Four European Countries
- Abstract 604P_PR, Poster Display Session: Gastrointestinal tumors, colorectal
- Monday, September 29, 12:45 – 1:45 PM (CET), Poster Area
- Adjuvant regorafenib (REG) in stage IV colorectal cancer (CRC) after curative treatment of liver metastases: a phase III randomized, placebo (PBO)-controlled trial (COAST)
- Abstract 611TiP, Poster Display Session: Gastrointestinal tumors, colorectal
- Monday, September 29, 12:45 – 1:45 PM (CET), Poster Area
- A prospective, observational trial to further assess safety and efficacy of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice (CORRELATE)
- Abstract 613TiP, Poster Display Session: Gastrointestinal tumors, colorectal
- Monday, September 29, 12:45 – 1:45 PM (CET), Poster Area
- Analysis of treatment patterns of patients with advanced gastrointestinal stromal tumors (GIST) in EU5
- Abstract 1427P, Poster Display Session: Sarcoma
- Monday, September 29, 12:45 – 1:45 PM (CET), Poster Area
Sorafenib
- Correlation of sorafenib exposure with safety and efficacy from pivotal clinical trials in hepatocellular carcinoma (HCC) and renal cell cancer (RCC)
- Abstract 485P, Poster Display Session: Developmental therapeutics
- Saturday, September 27, 12:45 – 1:45 PM (CET), Poster Area
- Health economic analysis of the randomized multicenter phase II trial SAKK 77/08: sorafenib with or without everolimus in patients with unresectable hepatocellular carcinoma (HCC)
- Abstract 1039P, Poster Display Session: Health economics
- Sunday, September 28, 12:45 – 1:45 PM (CET), Poster Area
- A phase III randomized, double-blind, trial comparing sorafenib plus capecitabine versus placebo plus capecitabine in the treatment of locally advanced or metastatic HER2-negative breast cancer (RESILIENCE)
- Oral Presentation LBA8, Proffered Paper Session: Breast cancer, metastatic
- Sunday, September 28, 2:10 – 3:45 PM (CET), Madrid Room
- Final analysis of overall survival per subgroups of HCC patients in the prospective, non-interventional INSIGHT study treated with sorafenib
- Abstract 728P, Poster Display Session: Gastrointestinal tumors, non-colorectal
- Monday, September 29, 12:45 – 1:45 PM (CET), Poster Area
- An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): OPTIMIS
- Abstract 743TiP, Poster Display Session: Gastrointestinal tumors, non-colorectal
- Monday, September 29, 12:45 – 1:45 PM (CET), Poster Area
Radium Ra 223 Dichloride (radium-223)
- External-beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial
- Abstract 768P, Poster Display Session: Genitourinary tumors, prostate
- Saturday, September 27, 12:45 – 1:45 PM, Poster Area
- 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from ALSYMPCA: characterization of hematologic safety profiles
- Abstract 769P, Poster Display Session: Genitourinary tumors, prostate
- Saturday, September 27, 12:45 – 1:45 PM, Poster Area
- Reasons for Patients (Pts) Discontinuing Study Treatment (Tx) in the Phase 3 ALSYMPCA Trial of Radium-223 Dichloride (Ra-223) in Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases (Mets)
- Abstract 770P, Poster Display Session: Genitourinary tumors, prostate
- Saturday, September 27, 12:45 – 1:45 PM, Poster Area
- ERA 223 – a phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (AA) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone-predominant metastatic castration-resistant prostate cancer (CRPC)
- Abstract 803TiP, Poster Display Session: Genitourinary tumors, prostate
- Saturday, September 27, 12:45 – 1:45 PM, Poster Area
- Safety of radium-223 dichloride (Ra) with docetaxel (D) in patients (pts) with bone metastases (mets) from castration-resistant prostate cancer (CRPC): a phase 1/2a clinical trial
- Abstract 765PD, Poster Discussion Session: Genitourinary tumors, prostate
- Sunday, September 28, 1:00 – 2:00 PM, Granada Room
About Regorafenib (Stivarga®)
Regorafenib is an oral multi-kinase inhibitor that inhibits various kinases within the mechanisms involved in tumor growth and progression – angiogenesis, oncogenesis and the tumor microenvironment. In preclinical studies, regorafenib inhibits several angiogenic VEGF receptor tyrosine kinases that play a role in tumor neoangiogenesis (the growth of new blood vessels). In addition to VEGFR 1-3 it also inhibits various oncogenic and tumor microenvironment kinases including TIE-2, RAF-1, BRAF, BRAFV600, KIT, RET, PDGFR, and FGFR, which individually and collectively impact upon tumor growth, formation of a stromal microenvironment and disease progression.
Regorafenib is approved under the brand name Stivarga® in more than 60 countries worldwide, including the U.S., Europe and Japan for the treatment of metastatic colorectal cancer. The product is also approved in more than 40 countries, including the U.S., Europe and Japan, for the treatment of metastatic gastrointestinal stromal tumors (GIST).
Regorafenib is a compound developed by Bayer. In 2011, Bayer entered into an agreement with Onyx Pharmaceuticals, Inc., an Amgen subsidiary, under which Onyx receives a royalty on all global net sales of regorafenib in oncology.
About Sorafenib (Nexavar®)
Sorafenib, an oral anti-cancer therapy, is approved under the brand name Nexavar® in more than 100 countries worldwide. In Europe, Nexavar is approved for the treatment of hepatocellular carcinoma (HCC); for the treatment of patients with advanced renal cell carcinoma (RCC) who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy; and for progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.
In preclinical studies, sorafenib has been shown to inhibit multiple kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth. These kinases include Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.
Nexavar is co-developed by Onyx Pharmaceuticals, Inc., an Amgen subsidiary, and Bayer, except in Japan where Bayer manages all development. The companies co-promote Nexavar in the U.S. Outside of the U.S., excluding Japan, Bayer has exclusive marketing rights, and Bayer and Onyx share profits globally.
About Radium-223 Dichloride (Xofigo®)
Radium-223 dichloride (radium-223) is a therapeutic alpha particle-emitting pharmaceutical with an anti-tumor effect on bone metastases. Radium-223 mimics calcium and selectively targets bone, specifically areas of bone metastases, by forming complexes with the bone mineral hydroxyapatite. The high linear energy transfer of alpha emitters leads to a high frequency of double-strand DNA breaks in adjacent tumor cells, resulting in a potent cytotoxic effect. The alpha particle range from radium-223 is less than 100 micrometers, which minimizes damage to the surrounding normal tissue.
Radium-223 dichloride has been approved under the brand name Xofigo® in more than 40 countries worldwide, including the U.S. and the EU. In Europe, it is approved for the treatment of adults with CRPC, symptomatic bone metastases and no known visceral metastases.
About Oncology at Bayer
Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.9 billion (2013), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 56,000 employees (Dec 31, 2013) and is represented in more than 100 countries. More information is available at www.healthcare.bayer.com.
Follow us on Facebook: www.facebook.com/healthcare.bayer
Follow us on Twitter: https://twitter.com/BayerHealthCare
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Downloads
RTF
Related Articles
Bayer to Present Data on Multiple Oncology Compounds at the European Cancer Congress (ECCO-ESMO-ESTRO) 2013Phase III Trial of Sorafenib in Combination with Capecitabine Does Not Meet Primary Endpoint in Patients with Advanced Breast CancerBayer Receives Approval for Nexavar® (sorafenib) in Japan for Treatment of Differentiated Thyroid Cancer
Links
Bayer HealthCare Pharmaceuticals
Contact
Anna Koch
Phone: +49 30 468-15942
Fax: +49 30 468-16710
E-Mail
Bayer Healthcare
Search Bayer HealthCare Links
Select Country Andina Region Argentina Cono Sur Austria (d) Australia Belgium Brazil Canada Chile China Central America Denmark (Bayer Norden) Finland France Germany Great Britain/Ireland Greece Italy Japan Korea Mexico Netherlands New Zealand Norway Poland Russia South Africa Spain Sweden Switzerland Taiwan Thailand Turkey Uruguay Bayer Cono Sur USA
Annual report Integrated Annual Report of Bayer AG 2013
RSS Feed
RSS Feed
PS - PS -PS - PPHM has it - stay LONG imo
I found another study (from 2011 - Uni Graz)
http://www.sciencedirect.com/science/article/pii/S0005273611002318
I´v got that articele from a friend - i´s from March 2013/Austrian newspaper.
I used Google to translate it into English
And again: it is PS - PHOSPHATIDYLSERIN
That´s the link:
http://derstandard.at/1362108241498/Krebskiller-aus-der-Muttermilch
Cancer killer of breast milk
Doris Griesser
March 12, 2013 , 18:30
A skin cancer cell , before and after treatment with the anti-tumor peptide : the formation of bubbles , and the red dye ( . RE) , capable of being received only by a damaged cell membrane , show that the cell death was initiated.
500x298 enlarge
photo : uni graz
A skin cancer cell , before and after treatment with the anti-tumor peptide : the formation of bubbles , and the red dye ( . RE) , capable of being received only by a damaged cell membrane , show that the cell death was initiated.
Tiny protein substances from the mother's milk are masters of natural immune defense - Graz researchers now want to use these peptides to the unerring control of hardly treatable cancers
The cancer therapy makes significant progress - and yet still half of all cancers is not completely curable . The disease may be years after treatment, recurrence , it can metastasize , and often have conventional therapies because of their poor marksmanship massive side effects .
A major goal of cancer research is therefore the development of specific therapies that destroy only the cancer cells but not healthy cells pull the affected. Scientists from the Department of Biophysics at the Institute for Molecular Bioscience at the Karl - Franzens - University Graz pursue a new strategy , in which they make human immune defense peptides for targeted cancer fighting cells fit .
Charge differences
One of these small proteins that have already taken preliminary studies very close look at the Graz researchers , is the lactoferricin occurring in breast milk . This natural immune defense peptide with its antibacterial and antiseptic effect destroys cancer cells without harming healthy tissue . The peptides dissolve the cancer cells own cell death inhibition and thus make practical aid for cancer cell suicide . The cause of their accuracy is how the researchers were able to demonstrate in a project funded by the Austrian Science Fund FWF project , in charge differences of peptides and the membrane surface of cancer cells . The positively charged peptides target due to the electrostatic interaction of the negatively charged membrane of the cancer cell surface and penetrate into them , while ignoring healthy cells with their neutral lipids in the outer membrane layer .
"I and my colleague Sabrina Riedl showed that cancer cells, the negatively charged phospholipid phosphatidylserine (PS ) in contrast to healthy cells on the outside of its membrane wear ," explains project manager Dagmar Zweytick . In various processes, such as in the formation of a cancer cell , namely, the negatively charged lipid folded outward and is in this way a reliable biomarker from . This in the professional world until the publication of Graz findings often doubted fact is of enormous importance , as it indicates the often difficult path for a targeted cancer treatment
In fact, we found that negatively charged lipid not only on the cell membrane of cell lines of various cancers , but also in the metastatic cells and primary cancer cells ," says Zweytick . In addition, the study suggests different skin tumors suggests that the exposed PS content with the malignancy of the tissue increases.
Brain tumor and melanoma
" In our biophysical studies, we were able to prove that the effective and selective for cancer cells actually use PS peptides as targets also . " On the basis of these revolutionary findings , the researchers have upgraded the cancer defense peptide lactoferricin for his fight against two particularly difficult to treat cancers : the malignant brain tumor ( glioblastoma ) and malignant melanoma , metastatic to skin cancer .
" We have the peptides initially , then optimized in model studies in cell cultures for these incurable cancers ," says Zweytick . " We have two derived from human lactoferricin peptide active ingredients selected and modified so that they developed a specific toxicity against glioblastoma and melanoma . " Meanwhile, the work is so far advanced that the human peptide derivatives in the current , also funded by the FWF project can be tested together with Beate Rinner of the Medical University of Graz in mice and further improved.
But why the natural peptides need to be changed at all ? " Since the peptides are fitted by nature only to ward off the first risk by bacteria , viruses or even cancer , they would fight against such a massive tumor lose ," said the scientist . " Due to our optimizations , we want to increase the effect of the peptides corresponding and simultaneously preventing the use of higher doses is toxic to healthy cells . "
Compared with chemotherapy , human peptide derivatives for the treatment of cancer have enormous advantages : " chemotherapy ," says Zweytick , " usually act on fast-growing cells - which are unfortunately not only the cancer cells is why it often leads to severe side effects that can be . . avoid with peptides , since they only attack cells carrying the negatively charged PS outside. " Even cancers that are as malignant melanoma to chemotherapy largely resistant , to be treatable using optimized peptides . And yet a great advantage have antitumor peptides : You can even find mutated cancer cells with altered genetic information .
However, the way these groundbreaking findings in the clinics is still a relatively continues: " The first step is done by filing a European patent application though, but we still need to improve the effectiveness and stability of the peptides so that they can really capture all the cancer cells," attenuates Dagmar Zweytick too impatient expectations . Are these challenges overcome , the valuable knowledge to be handed over to a drug company - to carry out the very expensive clinical trials.
the group of pphm-investors i know own about 0,5% of the outstandig shares - i think some of them will buy more when the sun will rise one day
all the pphm retail-investers i know have more than 26k pphm
bougth some more today too - and placed an order at 1,31 - let´s wait and see.......
pphm is my lagest position i ever had (after 25 years of hard stock-work ) nice weekende too all long longs
nice vol. at the end of this week!
i will sleep well tonight
after two glases of "Gelber Muskateller" from Styria
From the last CC:
(IST) that evaluated bavituximab in combination with paclitaxel in 13 patients with HER2-negative metastatic breast cancer are anticipated to be published in a manuscript in the near future. A Phase I/II IST evaluating bavituximab in combination with sorafenib in up to 48 patients with advanced hepatocellular carcinoma (liver cancer) has completed enrollment of the Phase II portion and data from this trial are expected to be presented at an upcoming conference.
Means to me: THIS YEAR mayby beginning of 2015
Means to me: THIS YAER
it´s green! i can´t believe it - go pphm!
"They" estimate 25 patients for pphm1202 in Romania
211k vol. who sold that? poor Boy!
I did!
you are 100% correct!
But if i were a patient i would search for every info i can get (not only from my doctor) - so for Germany: i think patients will also search/contact Charite (because it is extremely well known there) and you find "NSCLC" in the german texts.
So what can i/we do to make SUNRISE well known? (Facebook????)
So if you take the linke with "Charite Berlin" and you seach for "NSCLC" than you find our SUNRISE in Germany!